Perspective Therapeutics (NYSE:CATX) Raised to Moderate Buy at Royal Bank of Canada

Royal Bank of Canada upgraded shares of Perspective Therapeutics (NYSE:CATX - Free Report) from an outperform rating to a moderate buy rating in a report released on Tuesday, Marketbeat Ratings reports. Royal Bank of Canada currently has $16.00 price target on the stock, up from their prior price target of $15.00.

Several other research analysts also recently weighed in on CATX. Wedbush reiterated an "outperform" rating and issued a $11.00 target price on shares of Perspective Therapeutics in a research note on Tuesday, May 13th. Scotiabank started coverage on shares of Perspective Therapeutics in a research report on Friday, March 7th. They issued a "sector outperform" rating and a $15.00 price objective on the stock. HC Wainwright reissued a "buy" rating and issued a $10.00 price objective on shares of Perspective Therapeutics in a research note on Monday, March 31st. Truist Financial reduced their target price on shares of Perspective Therapeutics from $10.00 to $8.00 and set a "buy" rating for the company in a research note on Wednesday, May 14th. Finally, Cantor Fitzgerald raised shares of Perspective Therapeutics to a "strong-buy" rating in a report on Tuesday, March 4th. One analyst has rated the stock with a hold rating, six have given a buy rating and three have issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, Perspective Therapeutics currently has an average rating of "Buy" and a consensus price target of $12.63.

Perspective Therapeutics Price Performance

Shares of NYSE:CATX traded down $0.01 on Tuesday, reaching $3.12. The company's stock had a trading volume of 1,232,932 shares, compared to its average volume of 893,708. Perspective Therapeutics has a 52-week low of $1.60 and a 52-week high of $16.55. The stock's 50-day moving average is $2.29 and its two-hundred day moving average is $2.95.

Insider Transactions at Perspective Therapeutics

In other news, Director Robert F. Williamson III purchased 38,145 shares of the stock in a transaction that occurred on Monday, March 31st. The shares were acquired at an average price of $2.14 per share, for a total transaction of $81,630.30. Following the acquisition, the director now directly owns 108,982 shares in the company, valued at approximately $233,221.48. The trade was a 53.85% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Juan Graham acquired 33,333 shares of Perspective Therapeutics stock in a transaction that occurred on Friday, March 28th. The shares were purchased at an average cost of $2.25 per share, with a total value of $74,999.25. Following the completion of the acquisition, the chief financial officer now owns 35,354 shares of the company's stock, valued at $79,546.50. The trade was a 1,649.33% increase in their position. The disclosure for this purchase can be found here. Insiders have purchased a total of 115,696 shares of company stock valued at $256,344 in the last ninety days. 3.72% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in CATX. Millennium Management LLC acquired a new position in Perspective Therapeutics during the fourth quarter worth about $4,132,000. Nuveen LLC purchased a new position in shares of Perspective Therapeutics during the 1st quarter worth approximately $2,647,000. Affinity Asset Advisors LLC increased its stake in shares of Perspective Therapeutics by 71.1% during the 1st quarter. Affinity Asset Advisors LLC now owns 2,224,196 shares of the company's stock worth $4,738,000 after purchasing an additional 924,196 shares in the last quarter. Octagon Capital Advisors LP raised its position in shares of Perspective Therapeutics by 62.1% during the 4th quarter. Octagon Capital Advisors LP now owns 2,304,752 shares of the company's stock worth $7,352,000 after purchasing an additional 882,528 shares during the last quarter. Finally, Two Sigma Investments LP purchased a new stake in Perspective Therapeutics in the 4th quarter valued at approximately $2,075,000. Institutional investors and hedge funds own 54.66% of the company's stock.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.